ANNA GRESHAM: Open Payments
NPI 1194077636 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$518 in 25 payments from 10 companies in 2025. Trend: 2023 $152 · 2024 $531 · 2025 $518
Food & beverage: $518
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 7 | $171 |
| Abbott Laboratories | 5 | $129 |
| Novo Nordisk Inc | 5 | $74 |
| Lilly USA, LLC | 2 | $30 |
| SANOFI-AVENTIS U.S. LLC | 1 | $23 |
| Gilead Sciences, Inc. | 1 | $21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
| GlaxoSmithKline, LLC. | 1 | $20 |
| Exact Sciences Corporation | 1 | $15 |
| Amgen Inc. | 1 | $14 |
Products named: LEQVIO, FREESTYLE LIBRE 3, Wegovy, MOUNJARO, TZIELD, JASCAYD, AREXVY, OTEZLA.
Industry payments across TX — which companies pay providers there.
